eLife-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2020-03-03 ms4294801609865205

审稿速度:1.0
经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。
我的有意义，但因editor评估一修需2月以上，被拒

265 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2020-05-04 ms5441261199713928

审稿速度:2.0
经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！

191 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2020-02-23 Dr. H

elife被拒后，投了JCI，居然23天就给了小修

188 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2019-02-25 nanana

under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？

233 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2024-03-19 ms1000002034075033 来自天津

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：免疫
经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？

24 0

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2023-12-11 ms7000001972506279 来自北京

能收临床文章吗？

29 0

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2023-02-27 ms2000000333658765 来自上海

本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水

65 0

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2022-10-23 slientwo

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：生物学
经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。

59 0

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2022-05-19 alexib

看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。

171 0

[GetPortalCommentsPageByObjectIdResponse(id=858018, encodeId=d7cc85801894, content=审稿速度:1.0 经验分享：很难，需要一定的创新性和新颖性，比较重要的意义，且数据完整，证据充分。 我的有意义，但因editor评估一修需2月以上，被拒 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9c5414099, createdName=ms4294801609865205, createdTime=Tue Mar 03 21:24:58 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860181, encodeId=588b86018151, content=审稿速度:2.0 经验分享：elife在国际影响力是很高的年轻期刊，认可度也很高。国内学者在此期刊上发表论文还很少，总觉得期刊宣传力度不强。我们组投了一篇，送审回来的意见很多中肯的修改建议，希望最终发表成功！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eefb5414002, createdName=ms5441261199713928, createdTime=Mon May 04 19:53:27 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585231, encodeId=e86358523194, content=elife被拒后，投了JCI，居然23天就给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=188, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sun Feb 23 00:00:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567236, encodeId=d7e256e23667, content=under editorial assessment已经10天了，这个杂志不是审稿很快吗？各位有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/20/aa5f027eef24954fd6ccd032076f9966.jpg, createdBy=928193395, createdName=nanana, createdTime=Mon Feb 25 00:00:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2174237, encodeId=62e921e42375d, content=能收临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5476522798, createdName=ms7000001972506279, createdTime=Mon Dec 11 10:57:53 CST 2023, time=2023-12-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2116644, encodeId=4c5e2116644a5, content=本来就是先发预印本了。。再不拒稿。。。后面不知道会不会变水, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9acf8521381, createdName=ms2000000333658765, createdTime=Mon Feb 27 09:57:04 CST 2023, time=2023-02-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2095483, encodeId=2bba209548306, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：2013年才有第一个影响因子，老外很喜欢Elife杂志，Plos创始人之一接替之前的主编开始新的一轮改革。现在更喜欢接受新奇且抓人眼球的文章，风格和Plos biology太像了。看中的是文章是否提出新的概念，整体机制看中减少一些，生物学厚重感比EMBO reports差些。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Oct 23 07:40:34 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220898, encodeId=170112208983e, content=看了很多这上面的文章有点看明白了，那些工作量不大的文章（就是大家觉得有点水的文章）都属于Short Reports，应该类似其他杂志的letter，elife上正经的research article工作量基本都挺大，有些文章动辄30-40张图，而Short Reports对创新性要求很高，也很难中。elife明明可以把这些Short Reports当成letter发表，这样杂志的影响因子肯定会很高，但elife却不这样做，看来这个杂志真的不看重IF。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Thu May 19 11:33:55 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218532, encodeId=60f312185327e, content=牛批, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIZ7wT7fOlAz1USI4kh7pM7TEOKQcZjibKj42Hu6avoCoRy7aRZpzaCx4QAOD3WV5Xsmnv8AMmgBRA/132, createdBy=00422255419, createdName=suan60, createdTime=Tue May 10 19:27:58 CST 2022, time=2022-05-10, status=1, ipAttribution=)]

2022-05-10 suan60

牛批

180 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务